In Silico Transcriptomic Expression of MSR1 in Solid Tumors Is Associated with Responses to Anti-PD1 and Anti-CTLA4 Therapies
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25073987 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Adrián Sanvicente und 9 weiteren Autor:innen. Beteiligte Einrichtung: Experimental Therapeutics in Cancer Unit, Medical Oncology Department, Hospital Clínico San Carlos (HCSC), Instituto de Investigación Sanitaria (IdIS…. Hauptthemen laut MEDLINE: Melanoma, Skin Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto de Salud Carlos III, CRIS CANCER FOUNDATION, ACEPAIN, Diputación de Albacete, CIBERONC and the CRIS Cancer Foundation.
Abstract (Originalsprache)
Immuno-oncology has gained momentum with the approval of antibodies with clinical activities in different indications. Unfortunately, for anti-PD (L)1 agents in monotherapy, only half of the treated population achieves a clinical response. For other agents, such as anti-CTLA4 antibodies, no biomarkers exist, and tolerability can limit administration. In this study, using publicly available genomic datasets, we evaluated the expression of the macrophage scavenger receptor-A (SR-A) (MSR1) and its association with a response to check-point inhibitors (CPI). MSR1 was associated with the presence of macrophages, dendritic cells (DCs) and neutrophils in most of the studied indications. The presence of MSR1 was associated with macrophages with a pro-tumoral phenotype and correlated with TIM3 expression. MSR1 predicted favorable overall survival in patients treated with anti-PD1 (HR: 0.56, FDR: 1%, p = 2.6 × 10−5), anti PD-L1 (HR: 0.66, FDR: 20%, p = 0.00098) and anti-CTLA4 (HR: 0.37, FDR: 1%, p = 4.8 × 10−5). When specifically studying skin cutaneous melanoma (SKCM), we observed similar effects for anti-PD1 (HR: 0.65, FDR: 50%, p = 0.0072) and anti-CTLA4 (HR: 0.35, FDR: 1%, p = 4.1 × 10−5). In a different dataset of SKCM patients, the expression of MSR1 predicted a clinical response to anti-CTLA4 (AUC: 0.61, p = 2.9 × 10−2). Here, we describe the expression of MSR1 in some solid tumors and its association with innate cells and M2 phenotype macrophages. Of note, the presence of MSR1 predicted a response to CPI and, particularly, anti-CTLA4 therapies in different cohorts of patients. Future studies should prospectively explore the association of MSR1 expression and the response to anti-CTLA4 strategies in solid tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Experimental Therapeutics in Cancer Unit, Medical Oncology Department, Hospital Clínico San Carlos (HCSC), Instituto de Investigación Sanitaria (IdISSC), 28040 Madrid, Spain.
- Facultad de Ciencias Químicas, Universidad Complutense de Madrid, 28040 Madrid, Spain.
- Molecular Oncology Laboratory, Instituto de Investigación Sanitaria San Carlos (IdISSC), 28040 Madrid, Spain.
- Department of Bioinformatics, Semmelweis University, Tűzoltó u. 7-9, H-1094 Budapest, Hungary.
- Research Centre for Natural Sciences, Hungarian Research Network, Magyar Tudosok Korutja 2, H-1117 Budapest, Hungary.
- START Madrid-Fundación Jiménez Díaz (FJD) Early Phase Program, Fundación Jiménez Díaz Hospital, 28040 Madrid, Spain.
ORCID-Profile: Adrián Sanvicente, Igor López Cade, Alberto Ocaña
Förderung
- Instituto de Salud Carlos III
- CRIS CANCER FOUNDATION
- ACEPAIN, Diputación de Albacete, CIBERONC and the CRIS Cancer Foundation
- European Community through the regional development funding program
Zitieren
APA
Sanvicente, A., Díaz-Tejeiro, C., Nieto-Jiménez, C., Paniagua-Herranz, L., López Cade, I., Balázs, G., Moreno, V., Pérez-Segura, P., Calvo, E., & Ocaña, A. (2024). In Silico Transcriptomic Expression of MSR1 in Solid Tumors Is Associated with Responses to Anti-PD1 and Anti-CTLA4 Therapies. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25073987
Vancouver
Sanvicente A, Díaz-Tejeiro C, Nieto-Jiménez C, Paniagua-Herranz L, López Cade I, Balázs G, et al. In Silico Transcriptomic Expression of MSR1 in Solid Tumors Is Associated with Responses to Anti-PD1 and Anti-CTLA4 Therapies. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25073987
BibTeX
@article{Sanvicente2024,
author = {Sanvicente, Adrián and Díaz-Tejeiro, Cristina and Nieto-Jiménez, Cristina and Paniagua-Herranz, Lucia and López Cade, Igor and Balázs, Győrffy and Moreno, Víctor and Pérez-Segura, Pedro and Calvo, Emiliano and Ocaña, Alberto},
title = {In Silico Transcriptomic Expression of MSR1 in Solid Tumors Is Associated with Responses to Anti-PD1 and Anti-CTLA4 Therapies},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25073987}
}
EUVIMED